Christoph Lengauer

CSO & co-founder

2022 - Current

Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drug makers, seed capital, and best-of-breed services - everything a founder needs to get from concept to a compelling dataset that enables an awesome Series A financing. And we do this at scale for 40+ companies / year.

Adjunct Associate Professor

2005

Principal Investigator

1994 - 2005

Co-lead the molecular genetics lab together with Bert Vogelstein and Ken Kinzler. Was involved in the identification of several cancer driver genes incl. BRAF and PIK3CA. Discovered that all cancers are genetically unstable which explains the molecular heterogeneity of cancer and why cancers develop resistance to cancer drugs.

Consultant, R&D strategy

2021 - 2022

We envision a future where routine preventative care includes a blood test for cancer, just as patients are now routinely tested for early stages of heart disease. We know that if cancer is caught early, it often can be cured.

Chief Innovation Officer & co-founder

2019 - 2021

CEO & founder

2017 - 2022

Advise Connect Inspire (ACI) helps European life sciences startups and emerging companies. We provide tailored support for young companies ranging from high-level strategic guidance to operational and tactical assistance. We are convinced that the complexity of building and growing a life sciences company calls for programs that are flexible and built around the needs of each company. We also understand the unique challenges of European companies that are trying to navigate a new ecosystem, and we know how to best help them.

Partner

2018 - 2022

Third Rock’s strategy is to discover, launch and build great companies - based on bold ideas that meet at the intersection of science, strategy, business and medicine. Blueprint - Relay - Celsius - Thrive - MOMA

Venture Partner

2016 - 2018

Executive Vice President

2016 - 2021

Integrated Drug Development. Blueprint's singular focus is to use our deep understanding of the genetic blueprint of cancer and rare genetic diseases driven by the abnormal activation of kinases to craft highly selective medicines aimed at eradicating these diseases.

CSO

2012 - 2016

Chief Drug Hunter AYVAKIT (avapritinib) is a KIT/PDGFRA inhibitor approved for patients with advanced systemic mastocytosis (SM) and for patients with gastrointestinal stromal tumor (GIST), GAVRETO (pralsetinib) is a RET inhibitor approved for patients with RET+ non-small-cell lung carcinoma (NSCLC) and RET+ thyroid cancer.

CSO & co-founder

2020 - 2021

Molecular machines are enzymes that create force, work, and motion. We will discover the next generation of precision medicines by targeting the molecular machines that underlie human disease.

CSO, president & co-founder

2018 - 2020

How cells work together defines who we are, how we function and the diseases we have. Now, for the first time, we are able to see how individual cells interact at a level of resolution that was not previously possible.

Associate

2018 - 2019

The Creative Destruction Lab is a seed-stage program for massively scalable, science-based companies.

CEO

2015 - 2019